Evergreen Capital Management LLC Buys 67 Shares of argenx SE (NASDAQ:ARGX)

Evergreen Capital Management LLC boosted its stake in argenx SE (NASDAQ:ARGXFree Report) by 12.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 588 shares of the company’s stock after acquiring an additional 67 shares during the period. Evergreen Capital Management LLC’s holdings in argenx were worth $289,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Prelude Capital Management LLC raised its position in shares of argenx by 45.5% in the 2nd quarter. Prelude Capital Management LLC now owns 1,600 shares of the company’s stock worth $624,000 after acquiring an additional 500 shares in the last quarter. Orion Portfolio Solutions LLC lifted its stake in argenx by 64.8% in the third quarter. Orion Portfolio Solutions LLC now owns 7,531 shares of the company’s stock valued at $3,702,000 after buying an additional 2,962 shares during the period. Trexquant Investment LP acquired a new position in argenx in the third quarter valued at approximately $1,840,000. Barclays PLC boosted its holdings in shares of argenx by 429.5% during the 3rd quarter. Barclays PLC now owns 38,952 shares of the company’s stock worth $19,149,000 after buying an additional 31,596 shares in the last quarter. Finally, Raymond James & Associates grew its position in shares of argenx by 132.3% during the 3rd quarter. Raymond James & Associates now owns 33,771 shares of the company’s stock worth $16,603,000 after buying an additional 19,232 shares during the period. Institutional investors and hedge funds own 52.77% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ARGX. Evercore ISI cut their target price on shares of argenx from $594.00 to $436.00 and set an “outperform” rating on the stock in a research note on Thursday, December 21st. JPMorgan Chase & Co. reduced their target price on argenx from $615.00 to $560.00 and set an “overweight” rating for the company in a research note on Tuesday, December 5th. TD Cowen upped their price target on argenx from $612.00 to $641.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 12th. Citigroup reduced their price objective on argenx from $610.00 to $591.00 and set a “buy” rating for the company in a research note on Wednesday, November 29th. Finally, Deutsche Bank Aktiengesellschaft lowered argenx from a “buy” rating to a “hold” rating in a research report on Wednesday, December 20th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and an average price target of $530.42.

Read Our Latest Research Report on ARGX

argenx Stock Performance

NASDAQ:ARGX opened at $388.68 on Friday. The business’s fifty day moving average is $388.01 and its 200 day moving average is $447.93. The firm has a market cap of $23.05 billion, a price-to-earnings ratio of -75.62 and a beta of 0.65. argenx SE has a 52-week low of $327.73 and a 52-week high of $550.76.

argenx (NASDAQ:ARGXGet Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). The firm had revenue of $417.84 million during the quarter, compared to analysts’ expectations of $378.60 million. argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. During the same period in the previous year, the company posted ($0.70) earnings per share. Equities analysts predict that argenx SE will post -2.29 EPS for the current fiscal year.

argenx Profile

(Free Report)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.

Read More

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE (NASDAQ:ARGXFree Report).

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.